Author response: Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

Affiliations

Comment

Alasdair J Coles. Neurology. 2018.

. 2018 Sep 18;91(12):581-582.

doi: 10.1212/WNL.0000000000006203.

No abstract available

Comment on

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators. Coles AJ, et al. Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23. Neurology. 2017. PMID: 28835403 Free PMC article.
Reader response: Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
Avasarala J. Avasarala J. Neurology. 2018 Sep 18;91(12):580. doi: 10.1212/01.wnl.0000544324.09014.0e. Neurology. 2018. PMID: 30224507 No abstract available.